Return to QS81 Overview

Inflammatory bowel disease [QS81]

Measuring the use of this guidance

Statement: 1

People with suspected inflammatory bowel disease have a specialist assessment within 4 weeks of referral.

Quality standard measure: Evidence of local referral pathways to ensure that people with suspected inflammatory bowel disease have a specialist assessment within 4 weeks of referral.
What was measured: Proportion of service that reported that all urgent referrals were seen within 4 weeks or more rapidly if clinically necessary.
Data collection end: December 2013
73%
Number that met the criteria: 126 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.

Quality standard measure: Evidence of local referral pathways to ensure that people with suspected inflammatory bowel disease have a specialist assessment within 4 weeks of referral.
What was measured: Proportion of service that reported that there was outpatient access to ultrasound/CT/contrast studies and endoscopic assessment within 4 weeks.
Data collection end: December 2013
94%
Number that met the criteria: 163 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.


Statement: 2

Services provide age‑appropriate support from a multidisciplinary team for people with inflammatory bowel disease, and their family members or carers.

Quality standard measure: Evidence that services provide age‑appropriate support from a multidisciplinary team for people with inflammatory bowel disease, and their family members or carers.
What was measured: Proportion of services that reported that patients and their partners are given advice, when required, on issues regarding sexuality and body image. Teams can refer for specialist support locally as appropriate.
Data collection end: December 2013
63%
Number that met the criteria: 109 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.

Quality standard measure: Evidence that services provide age‑appropriate support from a multidisciplinary team for people with inflammatory bowel disease, and their family members or carers.
What was measured: Proportion of services that reported that there is a transitional care service within the Trust / Health Board for young people to support their transfer to adult services by 18‐19 years.
Data collection end: December 2013
53%
Number that met the criteria: 92 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.

Quality standard measure: Proportion of people with inflammatory bowel disease whose needs, and the needs of their family members or carers (if appropriate), for age-appropriate support from a multidisciplinary team are met.
What was measured: Percentage of adult patients seen by a member of the IBD team during their admission.
Data collection end: December 2013
91%
Number that met the criteria: 3982 / 4359
Area covered: UK
Source: Royal College of Physicians. National clinical audit of inpatient care for adults with ulcerative colitis: UK Inflammatory Bowel Disease audit.

Quality standard measure: Proportion of people with inflammatory bowel disease whose needs, and the needs of their family members or carers (if appropriate), for age-appropriate support from a multidisciplinary team are met.
What was measured: Percentage of paediatric patients seen by a paediatric IBD nurse during admission.
Data collection end: December 2013
71%
Number that met the criteria: 211 / 298
Area covered: UK
Source: Royal College of Physicians. National clinical audit of inpatient care for young people with ulcerative colitis: UK Inflammatory Bowel Disease audit.


Statement: 3

People having surgery for inflammatory bowel disease have it undertaken by a colorectal surgeon who is a core member of the inflammatory bowel disease multidisciplinary team.

Quality standard measure: Evidence of local arrangements to ensure that people having surgery for inflammatory bowel disease have it undertaken by a colorectal surgeon who is a core member of the inflammatory bowel disease multidisciplinary team.
What was measured: Proportion of services that reported that the IBD team is made up of at least a consultant gastroenterologist, an IBD nurse specialist, stoma nurse, dietitian, and a consultant colorectal surgeon.
Data collection end: December 2013
70%
Number that met the criteria: 121 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.


Statement: 4

People receiving drug treatment for inflammatory bowel disease are monitored for adverse effects.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: The percentage of all adult patients receiving treatment with biological therapies for whom an adverse reaction was recorded at 3 month follow-up.
Data collection end: February 2016
10%
Number that met the criteria: 82 / 855
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: The percentage of all paediatric patients receiving treatment with biological therapies for whom an adverse reaction was recorded at initial treatment.
Data collection end: February 2016
1%
Number that met the criteria: 4 / 278
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: Proportion of people receiving drug treatment for inflammatory bowel disease who are monitored for adverse effects.
What was measured: Proportion of all paediatric patients receiving treatment with biological therapies for whom an adverse reaction was recorded at 3 month follow-up.
Data collection end: February 2016
5%
Number that met the criteria: 6 / 121
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: Evidence of documented local safety policies and procedures to monitor for adverse effects in people receiving drug treatment for inflammatory bowel disease.
What was measured: Proportion of services that reported that patients receiving biological therapy are reviewed at least 3 monthly (either directly or by email/telephone) to monitor efficacy and adverse effects.
Data collection end: December 2013
71%
Number that met the criteria: 122 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.

Quality standard measure: Evidence of documented local safety policies and procedures to monitor for adverse effects in people receiving drug treatment for inflammatory bowel disease.
What was measured: Proportion of services that reported that clear shared care arrangements for the monitoring and prescribing of immunosuppressive drugs are in place between primary and secondary care, including advice on the frequency of monitoring and what to do in the event of abnormal results.
Data collection end: December 2013
73%
Number that met the criteria: 126 / 173
Area covered: UK
Source: Royal College of Physicians. National audit of inflammatory bowel disease service provision: UK Inflammatory Bowel Disease audit.

Quality standard measure: The number of adverse events reported because of drug treatment for inflammatory bowel disease.
What was measured: Proportion of patients taking biological therapy with an adverse reaction recorded during initial treatment.
Data collection end: February 2015
3%
Number that met the criteria: 97 / 3531
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.

Quality standard measure: The number of adverse events reported because of drug treatment for inflammatory bowel disease.
What was measured: Proportion of patients taking biological therapy with an adverse reaction recorded during initial treatment.
Data collection end: February 2016
4%
Number that met the criteria: 117 / 2722
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.



 Return to QS81 Overview